Search Results

Amonafide 10mg  | Purity Not Available

Selleck Chemicals

Amonafide (NSC308847, AS1413) produces protein-associated DNA-strand breaks through a topoisomerase II-mediated reaction, but does not produce topoisomerase I-mediated DNA cleavage. Phase 3.

More Information Supplier Page

Lidocaine 50mg  | Purity Not Available

Selleck Chemicals

Lidocaine (Alphacaine) is a selective inverse peripheral histamine H1-receptor agonist with an IC50 of >32 μM.

More Information Supplier Page

Loratadine 50mg  | Purity Not Available

Selleck Chemicals

Loratadine is a histamine H1 receptor antagonist, used to treat allergies. Also acts as a selective inhibitor of B(0)AT2 with IC50 of 4 μM.

More Information Supplier Page

Losartan Potassium 50mg  | Purity Not Available

Selleck Chemicals

Losartan Potassium is an angiotensin II receptor antagonist, competes with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.

More Information Supplier Page

Losartan Potassium 10mM/1mL  | Purity Not Available

Selleck Chemicals

Losartan Potassium is an angiotensin II receptor antagonist, competes with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.

More Information Supplier Page

MGCD-265 analog 50mg  | Purity Not Available

Selleck Chemicals

MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively; also inhibits Ron and Tie2. Phase 1/2.

More Information Supplier Page

MGCD-265 analog 10mM/1mL  | Purity Not Available

Selleck Chemicals

MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively; also inhibits Ron and Tie2. Phase 1/2.

More Information Supplier Page

Rigosertib (ON-01910) 5mg  | Purity Not Available

Selleck Chemicals

Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Rigosertib inhibits PI3K/Akt pathway and activates oxidative stress signals. Rigosertib induces apoptosis in various cancer cells. Phase 3.

More Information Supplier Page